Actualités
Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.
Weight loss drug stock leaders slumped on Friday amid updates and ahead of earnings. NVO stock sank under a buy point on trial results. LLY stock dived below support with earnings due next week. Updating the closely watched ZEUS phase 3 clinical trial, Denmark's Novo Nordisk announced overnight that its experimental cardiovascular drug, ziltivekimab — to treat heart disease, kidney disease and inflammation — failed in the late-stage trial.
The Danish drugmaker is striving to diversify beyond its popular weight-loss drugs, but its anti-inflammatory drug candidate faces a challenge.
Shares fell after a late-stage cardiovascular trial failed to meet its main goal.
Trial enrolled more than 6,300 patients with cardiovascular and kidney disease
Novo’s Phase 3 trial showed that investigational drug Ziltivekimab did not reduce major adverse cardiovascular events compared with the placebo
U.S.-listed shares of Novo Nordisk closed Thursday up just 1% this year.
The experimental anti-inflammatory drug ziltivekimab did not reduce major adverse cardiovascular events compared with a placebo in a study of more than 6,300 patients
Novo Nordisk shares dropped after the Danish drugmaker said an experimental medicine didn't reduce risk of major adverse cardiovascular events in a late-stage trial. The company's Denmark-listed stock was down nearly 10%, while its American depositary receipts fell about 9% in premarket trading in New York.
Investing.com -- Novo Nordisk (NYSE: NVO) shares dropped 10% Friday after the drugmaker revealed its experimental drug, ziltivekimab, failed to cut cardiovascular risk in a late-stage clinical trial.
The stock was down 9.5% after the company’s experimental medicine ziltivekimab didn’t achieve the expected risk reduction for major cardiovascular events.
Pfizer (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) offer unique divergent investment opportunities in the pharmaceutical industry. While one acts as a value and income play, the other stands out as a solid growth investment supported by rapid expansion in obesity and diabetes franchises. Pfizer Value Investment Play Pfizer (NYSE:PFE) has seen its valuation drop […]
Earlier this month, the European Commission granted marketing authorisation for Novo Nordisk’s once-daily Wegovy oral pill for obesity across all EU member states, while Crux announced a collaboration with the company to expand affordable, simplified access to authentic anti-obesity medications like Wegovy for US employer health plans. The combination of Europe’s first GLP-1 obesity tablet approval and a new US pharmacy-benefit carve-out could meaningfully influence how widely and...
Novo Nordisk (CPSE:NOVO B) has partnered with Crux to expand access to anti obesity medicines such as Wegovy for employer health plans in the United States. The collaboration focuses on simpler benefit designs and more predictable pricing for employer sponsored coverage. The initiative targets affordability and access barriers for GLP 1 obesity treatments for covered employees and dependents. Novo Nordisk is a major player in obesity care and GLP 1 therapies, and Wegovy is one of its key...
They may profit from the rapidly growing GLP-1 market in very different ways.
Novo Nordisk's Q2 results are set to spotlight Ozempic and Wegovy sales as oral launches and label expansions drive growth amid mounting competitive pressure.
Will this pharma company become a new leader in the weight loss market?
Novo Nordisk (NVO) reached $50.96 at the closing of the latest trading day, reflecting a +2.6% change compared to its last close.
Trailing a powerful competitor, Novo Nordisk could stay firmly in second place for a good while.
Novo Nordisk A/S (NYSE:NVO) was at the center of media coverage as it sued rival weight loss drug manufacturer Eli Lilly on Tuesday. The firm claimed that Lilly had run misleading advertisements about its weight loss drug when it came to touting their superior performance over Novo Nordisk A/S (NYSE:NVO)’s products. It claimed that Lilly […]
Healthcare stocks rose late Friday afternoon, with the NYSE Healthcare Index up 0.6% and the State S
Eli Lilly just won FDA clearance for an oral GLP-1 that targets over one billion potential patients worldwide, and the stock has barely moved. Here is whether that disconnect signals a buying opportunity or a trap.
Novo Nordisk is accusing Eli Lilly of deceptive advertising about GLP-1 drugs.
Novo Nordisk (CPSE:NOVO B) has filed a federal lawsuit against Eli Lilly over alleged false and misleading advertising of GLP-1 obesity and diabetes drugs. The company argues that Eli Lilly’s ads misrepresent clinical comparisons and risk misleading consumers and healthcare professionals. The case highlights rising tensions as both companies compete in the fast growing market for GLP-1 based obesity and diabetes treatments. Novo Nordisk is a major player in diabetes and obesity treatments,...
European stock markets closed higher in Friday trading as the eurozone private sector expanded in Ju
(Updates with responses from Novo Nordisk and Eli Lilly in the fourth and fifth paragraphs.) Novo
Novo Nordisk (CPSE:NOVO B) is back in focus after the European Commission granted marketing authorisation for its once daily Wegovy pill across all EU member states, creating a new oral option in GLP 1 obesity treatment. See our latest analysis for Novo Nordisk. The Wegovy pill approval lands at a time when Novo Nordisk’s 90 day share price return of 23.22% suggests momentum is still building, even as the year to date share price return is down 3.01% and the 1 year total shareholder return...
European equities traded in the US as American depositary receipts were tracking higher late Friday